Nothing Special   »   [go: up one dir, main page]

OA11435A - Matrix metalloprotease inhibitors. - Google Patents

Matrix metalloprotease inhibitors. Download PDF

Info

Publication number
OA11435A
OA11435A OA1200000188A OA1200000188A OA11435A OA 11435 A OA11435 A OA 11435A OA 1200000188 A OA1200000188 A OA 1200000188A OA 1200000188 A OA1200000188 A OA 1200000188A OA 11435 A OA11435 A OA 11435A
Authority
OA
OAPI
Prior art keywords
mmol
phenyl
amino
carbonyl
alkyl
Prior art date
Application number
OA1200000188A
Other languages
English (en)
Inventor
Kevin Neil Dack
Michael Jonathan Fray
Roger Peter Dickinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800510.1A external-priority patent/GB9800510D0/en
Priority claimed from GBGB9811843.3A external-priority patent/GB9811843D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA11435A publication Critical patent/OA11435A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
OA1200000188A 1998-01-09 2000-06-23 Matrix metalloprotease inhibitors. OA11435A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800510.1A GB9800510D0 (en) 1998-01-09 1998-01-09 Therapeutic agents
GBGB9811843.3A GB9811843D0 (en) 1998-06-02 1998-06-02 Therapeutic agents

Publications (1)

Publication Number Publication Date
OA11435A true OA11435A (en) 2004-04-28

Family

ID=26312925

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000188A OA11435A (en) 1998-01-09 2000-06-23 Matrix metalloprotease inhibitors.

Country Status (37)

Country Link
US (1) US6350907B1 (tr)
EP (1) EP1047665B1 (tr)
JP (1) JP3621884B2 (tr)
KR (1) KR100385662B1 (tr)
CN (1) CN1284942A (tr)
AP (1) AP1059A (tr)
AR (1) AR014270A1 (tr)
AT (1) ATE252547T1 (tr)
AU (1) AU736511B2 (tr)
BG (1) BG104575A (tr)
BR (1) BR9813719A (tr)
CA (1) CA2317604C (tr)
CO (1) CO4990971A1 (tr)
CZ (1) CZ20002459A3 (tr)
DE (1) DE69819206T2 (tr)
DK (1) DK1047665T3 (tr)
DZ (1) DZ2701A1 (tr)
EA (1) EA002971B1 (tr)
ES (1) ES2209244T3 (tr)
HN (1) HN1998000199A (tr)
HR (1) HRP20000460A2 (tr)
HU (1) HUP0101300A3 (tr)
IL (1) IL136889A0 (tr)
IS (1) IS5531A (tr)
MA (1) MA26594A1 (tr)
NO (1) NO20003506D0 (tr)
NZ (1) NZ504683A (tr)
OA (1) OA11435A (tr)
PA (1) PA8466101A1 (tr)
PE (1) PE20000176A1 (tr)
PL (1) PL342763A1 (tr)
PT (1) PT1047665E (tr)
SI (1) SI1047665T1 (tr)
SK (1) SK10112000A3 (tr)
TN (1) TNSN99002A1 (tr)
TR (1) TR200001909T2 (tr)
WO (1) WO1999035124A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356919A1 (en) * 1998-12-31 2000-07-13 Michael J. Janusz Selective inhibitors of mmp-12
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
BR0207307A (pt) * 2001-02-16 2004-08-17 Allelix Neuroscience Inc Inibidores de glyt-1
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040138103A1 (en) * 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2004266896B2 (en) * 2003-08-23 2010-08-19 Merck Serono Sa Derivatives of hydroxamic acid as metalloproteinase inhibitors
ES2545688T3 (es) * 2006-09-29 2015-09-15 F. Hoffmann-La Roche Ag Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide
CN104788333B (zh) * 2015-03-19 2017-03-22 中国医科大学 2‑取代‑9,10‑蒽醌类化合物、制备方法及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
CA2149640A1 (en) 1992-11-25 1994-06-09 Kevin T. Chapman Carboxy-peptidyl derivatives as antidegenerative active agents
ATE182137T1 (de) 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
BR9506535A (pt) 1994-01-20 1997-09-16 British Biotech Pharm Inibidores de metaloproteinases
ES2139183T3 (es) 1994-01-22 2000-02-01 British Biotech Pharm Inhibidores de las metaloproteinasas.
US6028110A (en) 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US5461746A (en) * 1995-01-17 1995-10-31 Tdw Delaware, Inc. Magnetic cleaning pig
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
ES2184861T3 (es) 1995-05-10 2003-04-16 Darwin Discovery Ltd Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica.
JPH11504934A (ja) 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとtnfの放出を抑制するペプチジル化合物およびその治療的使用
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU736511B2 (en) 2001-07-26
EP1047665A1 (en) 2000-11-02
HUP0101300A2 (hu) 2001-08-28
NZ504683A (en) 2002-06-28
JP3621884B2 (ja) 2005-02-16
DE69819206T2 (de) 2004-04-15
CZ20002459A3 (cs) 2001-12-12
NO20003506L (no) 2000-07-07
EP1047665B1 (en) 2003-10-22
SI1047665T1 (en) 2004-02-29
ATE252547T1 (de) 2003-11-15
NO20003506D0 (no) 2000-07-07
KR20010033990A (ko) 2001-04-25
AR014270A1 (es) 2001-02-07
KR100385662B1 (ko) 2003-05-28
TNSN99002A1 (fr) 2005-11-10
HRP20000460A2 (en) 2001-06-30
DK1047665T3 (da) 2004-02-02
CA2317604C (en) 2004-12-21
PL342763A1 (en) 2001-07-02
DE69819206D1 (de) 2003-11-27
IL136889A0 (en) 2001-06-14
AP1059A (en) 2002-04-22
PE20000176A1 (es) 2000-03-10
CN1284942A (zh) 2001-02-21
JP2002500215A (ja) 2002-01-08
WO1999035124A1 (en) 1999-07-15
CO4990971A1 (es) 2000-12-26
AU2277699A (en) 1999-07-26
PA8466101A1 (es) 2000-05-24
EA002971B1 (ru) 2002-12-26
DZ2701A1 (fr) 2003-09-01
TR200001909T2 (tr) 2000-12-21
IS5531A (is) 2000-06-13
BG104575A (en) 2001-02-28
HN1998000199A (es) 2000-11-03
BR9813719A (pt) 2000-10-17
US6350907B1 (en) 2002-02-26
HUP0101300A3 (en) 2002-11-28
AP9901436A0 (en) 1999-03-31
EA200000628A1 (ru) 2001-02-26
PT1047665E (pt) 2004-01-30
SK10112000A3 (sk) 2002-02-05
CA2317604A1 (en) 1999-07-15
MA26594A1 (fr) 2004-12-20
ES2209244T3 (es) 2004-06-16

Similar Documents

Publication Publication Date Title
US5300501A (en) Peptidyl derivatives
US5658929A (en) Sulfonamide fibrinogen receptor antagonists
US6642252B2 (en) Acid derivatives useful as serine protease inhibitors
OA11435A (en) Matrix metalloprotease inhibitors.
JPH0660144B2 (ja) シクロアルキル置換されたグルタルアミド抗高血圧剤
AU4411797A (en) Thrombin inhibitors
PL198032B1 (pl) Pochodne amidów, sposób ich wytwarzania, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
AU2011306396A1 (en) Matrix metalloproteinase inhibitors
KR20000048639A (ko) 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
SK174899A3 (en) Urokinase inhibitors
WO1994012169A1 (en) Carboxy-peptidyl derivatives as antidegenerative active agents
JP2002542228A (ja) Mmp阻害剤
EP1283825B1 (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
EP0318859A2 (en) N-substituted mercaptopropanamide derivatives
MXPA00006761A (en) Matrix metalloprotease inhibitors
US5773428A (en) Matrix metalloprotease inhibitors
HRP960260A2 (en) Hover boat